title: ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)].
abstract: OBJECTIVE
  To present our own experience with pegylated liposomal doxorubicin applied in ovarian cancer patients.
  
  
  METHODS
  The group of 32 patients with ovarian cancer was treated with pegylated liposomal doxorubicin (LPD) in Klinika Onkologii Klinicznej Centrum Onkologii Branch Gliwice between the years 2004 and 2007. Median age was 47 years. The histoclinical variables potentially influencing the occurrence of the hand-foot syndrome were analyzed.
  
  
  RESULTS
  Hand-foot syndrome has been observed in 11 patients (34.4%) treated with the LPD. The lesions have been present on the skin of hands, feet, elbow and knee joints and armpits. In the analyzed group of patients, the risk of the hand-foot syndrome occurrence increased, however non-significantly, with the increase of number of cycles including LPD (p=0.069) and the number of previous lines of chemotherapy (p=0.067). Other analyzed factors had no negative influence on the hand-foot syndrome occurrence.
  
  
  CONCLUSIONS
  It is important to inform the patients about the risk of the hand-foot syndrome occurrence and its management. Early diagnosis allows to prevent the worsening of the hand-foot syndrome and makes it possible to continue the chemotherapy without the necessity of dose reduction and breaking from the therapy.
authors.affiliation: Klinika Onkologii Klinicznej Centrum Onkologii, Instytut Oddział w Gliwicach.
authors.forename: Izolda
authors.initials: I
authors.lastname: Mrochen-Domin
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Nowara
authors.forename: Beata
authors.initials: B
authors.lastname: Kaleta
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004890:Erythema / Q000139:chemically induced* / Q000517:prevention & control; D005260:Female; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000517:prevention & control; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010292:Paresthesia / Q000139:chemically induced* / Q000517:prevention & control; D011044:Poland; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D013577:Syndrome
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin